Barclays Keeps Their Buy Rating on Quidel Corp


Barclays analyst Jack Meehan maintained a Buy rating on Quidel Corp (NASDAQ: QDEL) yesterday and set a price target of $65. The company’s shares closed yesterday at $60.15, close to its 52-week high of $61.13.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 9.0% and a 61.4% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Genomic Health, Waters Corp, and Illumina.

Quidel Corp has an analyst consensus of Strong Buy, with a price target consensus of $62.80.

See today’s analyst top recommended stocks >>

Based on Quidel Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $33.96 million. In comparison, last year the company had a net profit of $14.29 million.

Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of QDEL in relation to earlier this year. Most recently, in February 2018, Kenneth Buechler, a Director at QDEL bought 12,154 shares for a total of $197,503.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes immunoassays, molecular, virology, and specialty products. Immunoassay tests are for physician offices, hospital laboratories, emergency departments, pharmacies, and other urgent care or alternative site settings.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts